Pfizer Inc. vs Merck & Co.
Side-by-side: ratings, scores, SEC red flags and conviction — all deterministic.
| Company | Pfizer Inc. (PFE) Sell Score -0.49 · 83% conf. Red flags: 21 Receivables outpacing revenue: Accounts receivable grew -0.9% YoY vs revenue growth of -41.1%. The +40.2% spread suggests extended credit terms, channel stuffing risk, or collection deterioration. Investigate the allowance for doubtful accounts and DSO trend. Bull 2 · Bear 8 | Merck & Co. (MRK) Hold Score -0.11 · 82% conf. Red flags: 12 Free cash flow deteriorating: FCF declined +37.8% YoY (from $14.71B to $9.14B). With OCF at $13.01B and capex at $3.86B, cash generation capacity is weakening — monitor for dividend/buyback sustainability. Bull 4 · Bear 6 |
Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.